Michael House
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael House has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Simona Socrate
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
10 shared publications- David Lee Kaplan
Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA
9 shared publications Yali Zhang
Mother Infant Research Center, Tufts Medical Center, Boston, MA
5 shared publications- Kristin Marie Myers
Columbia University
4 shared publications Errol R. Norwitz
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Tufts Medical Center, Boston, MA, USA
3 shared publications- Simona Socrate
Massachusetts Institute of Technology, Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA
3 shared publications
Latest Publications
- 25 February 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (3) , 101886
Assisted reproductive technology is not associated with a short cervix: secondary analysis of the nuMoM2b dataset
- 25 February 2026
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 8 (3) , 101886
Assisted reproductive technology is not associated with a short cervix: secondary analysis of the nuMoM2b dataset
- 23 November 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 6 (1) , 101236
Preclinical testing of a prototype medical device to treat cervical insufficiency
- 23 November 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 6 (1) , 101236
Preclinical testing of a prototype medical device to treat cervical insufficiency
- 9 October 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 230 (5) , 555.e1-555.e8
Cerclage prevents ascending intrauterine infection in pregnant mice
- 9 October 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 230 (5) , 555.e1-555.e8
Cerclage prevents ascending intrauterine infection in pregnant mice
- 29 September 2023
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 41 (S 01) , e2978-e2984
Urgent Follow-up after Outpatient Nonstress Tests and the Potential for Fetal Monitoring at Home
Objective This study aimed to measure the proportion of patients needing urgent clinical follow-up after an abnormal outpatient nonstress test (NST). We further sought to capture the patient perspective on the acceptability of performing NSTs at home. Study Design A retrospective cohort study was performed over a 2-year period to determine the frequency of abnormal NSTs in a hospital-based, antepartum testing unit in patients greater than or equal to 32 weeks' gestation. The proportion of patients who delivered within 24 hours of an abnormal NST was also determined. A cross-sectional, web-based patient survey was conducted to obtain insight into the patient's comfort level with potentially performing NSTs at home. Results The chart review yielded 665 patients who underwent 2,122 NSTs at greater than or equal to 32 weeks. Of the 2,122 NSTs, 111 were categorized as abnormal and required urgent clinical follow-up, or 5.2% (95% confidence interval [CI] 4.3, 6.3%). Of the 665 patients, 13 delivered within 24 hours of an abnormal NST, or 2.0% (95% CI 1.0, 3.3%). In the web-based survey, the proportion of respondents who would feel comfortable or very comfortable conducting NSTs at home was 87/125, or 69.6% (95% CI 60.9, 77.1%). Conclusion This study revealed that 5.2% of NSTs performed in a hospital-based antepartum testing unit were abnormal and required urgent clinical follow-up. Of the patients being followed in the antepartum testing unit, 2.0% delivered within 24 hours of an abnormal NST. The majority of the survey respondents indicated they would feel comfortable performing NSTs at home. The present study adds important information regarding the risks and benefits of NSTs at home. Key Points
- 29 September 2023
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 41 (S 01) , e2978-e2984
Urgent Follow-up after Outpatient Nonstress Tests and the Potential for Fetal Monitoring at Home
Objective This study aimed to measure the proportion of patients needing urgent clinical follow-up after an abnormal outpatient nonstress test (NST). We further sought to capture the patient perspective on the acceptability of performing NSTs at home. Study Design A retrospective cohort study was performed over a 2-year period to determine the frequency of abnormal NSTs in a hospital-based, antepartum testing unit in patients greater than or equal to 32 weeks' gestation. The proportion of patients who delivered within 24 hours of an abnormal NST was also determined. A cross-sectional, web-based patient survey was conducted to obtain insight into the patient's comfort level with potentially performing NSTs at home. Results The chart review yielded 665 patients who underwent 2,122 NSTs at greater than or equal to 32 weeks. Of the 2,122 NSTs, 111 were categorized as abnormal and required urgent clinical follow-up, or 5.2% (95% confidence interval [CI] 4.3, 6.3%). Of the 665 patients, 13 delivered within 24 hours of an abnormal NST, or 2.0% (95% CI 1.0, 3.3%). In the web-based survey, the proportion of respondents who would feel comfortable or very comfortable conducting NSTs at home was 87/125, or 69.6% (95% CI 60.9, 77.1%). Conclusion This study revealed that 5.2% of NSTs performed in a hospital-based antepartum testing unit were abnormal and required urgent clinical follow-up. Of the patients being followed in the antepartum testing unit, 2.0% delivered within 24 hours of an abnormal NST. The majority of the survey respondents indicated they would feel comfortable performing NSTs at home. The present study adds important information regarding the risks and benefits of NSTs at home. Key Points
- Open Access
- 29 January 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (4) , 100881
Measurement of cervical softness before cerclage placement with an aspiration-based device
- 29 January 2023
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 5 (4) , 100881
Open AccessMeasurement of cervical softness before cerclage placement with an aspiration-based device
- Open Access
- 22 December 2022
- Published by IOP Publishing in Journal of Physics: Materials
- Vol. 6 (1) , 012501
Roadmap on biomaterials for women’s health
The application of engineering tools and techniques to studying women’s health, including biomaterials-based approaches, is a research field experiencing robust growth. Biomaterials are natural or synthetic materials used to repair or replace damaged tissues or organs or replicate an organ’s physiological function. However, in addition to in vivo applications, there has been substantial recent interest in biomaterials for in vitro systems. Such artificial tissues and organs are employed in drug discovery, functional cell biological investigations, and basic research that would be ethically impossible to conduct in living women. This Roadmap is a collection of 11 sections written by leading and up-and-coming experts in this field who review and discuss four aspects of biomaterials for women’s health. These include conditions that disproportionately but not exclusively affect women (e.g. breast cancer), conditions unique to female reproductive organs, in both non-pregnant and pregnant states, and sex differences in non-reproductive tissues (e.g. the cardiovascular system). There is a strong need to develop this exciting field, with the potential to materially influence women’s lives worldwide.
- 22 December 2022
- Published by IOP Publishing in Journal of Physics: Materials
- Vol. 6 (1) , 012501
Open AccessRoadmap on biomaterials for women’s health
The application of engineering tools and techniques to studying women’s health, including biomaterials-based approaches, is a research field experiencing robust growth. Biomaterials are natural or synthetic materials used to repair or replace damaged tissues or organs or replicate an organ’s physiological function. However, in addition to in vivo applications, there has been substantial recent interest in biomaterials for in vitro systems. Such artificial tissues and organs are employed in drug discovery, functional cell biological investigations, and basic research that would be ethically impossible to conduct in living women. This Roadmap is a collection of 11 sections written by leading and up-and-coming experts in this field who review and discuss four aspects of biomaterials for women’s health. These include conditions that disproportionately but not exclusively affect women (e.g. breast cancer), conditions unique to female reproductive organs, in both non-pregnant and pregnant states, and sex differences in non-reproductive tissues (e.g. the cardiovascular system). There is a strong need to develop this exciting field, with the potential to materially influence women’s lives worldwide.
- 22 September 2022
- Published by Springer Nature
- p. 48-59
Automated Segmentation of Cervical Anatomy to Interrogate Preterm Birth
- 22 September 2022
- Published by Springer Nature
- p. 48-59
Automated Segmentation of Cervical Anatomy to Interrogate Preterm Birth
- 28 March 2022
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 22
Tissue engineering for cervical function in pregnancy
- 28 March 2022
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 22
Tissue engineering for cervical function in pregnancy
- 16 April 2020
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 26 (7-8) , 379-386
Injectable Silk-Based Hydrogel as an Alternative to Cervical Cerclage: A Rabbit Study
Background: Preterm birth is a common cause of morbidity and mortality in newborn infants. Cervical insufficiency (CI) is a significant cause of preterm birth. The treatment for CI is cerclage, which is a suture placed around the cervix to provide mechanical support. Cerclage, however, is associated with limited efficacy. Here we present an injectable, silk-based hydrogel as an alternative to cerclage. Objective: Pregnant rabbits were used as an animal model of pregnancy to study the mechanical properties, biocompatibility, and degradation of the hydrogel after cervical injection. Study Design: Silk hydrogel (200 μL volume) was injected into the cervix. Controls were either injected with saline or treated with cerclage (5-0 polyethylene terephthalate suture). To study the effect on mechanical properties, the cervix was tested in compression. Biodegradation of the hydrogel was followed over 6 weeks. For biocompatibility, expression levels of proinflammatory mediators were studied. Results: Hydrogel injection resulted in significant tissue augmentation—the cross-sectional area of the cervix increased 46.3 ± 3.0%. The modulus of the uninjected and hydrogel-injected tissues was 3.3 ± 0.7 and 3.2 ± 0.5 kPa at 5–10% strain, respectively ( p = 0.8). Histology showed a mild inflammatory response surrounding the hydrogel. Biodegradation of the hydrogel showed 70% volume loss over 6 weeks. Hydrogel-injected tissue showed similar inflammatory response compared with cerclage. Conclusions: In pregnant rabbits, cervical injection of the silk-based hydrogel was biocompatible and naturally degraded. No adverse effects on timing of delivery and pup viability were seen. Silk-based hydrogels show promise for tissue augmentation during pregnancy. Impact Statement: This research describes the use of injectable silk-based hydrogel for augmenting cervical tissue in vivo in a pregnant rabbit model. Further preclinical development of the methods and insights described in this article can lead to therapeutic use of this hydrogel as an alternative to cerclage in preterm birth due to cervical insufficiency.
- 16 April 2020
- Published by SAGE Publications in Tissue Engineering Part A
- Vol. 26 (7-8) , 379-386
Injectable Silk-Based Hydrogel as an Alternative to Cervical Cerclage: A Rabbit Study
Background: Preterm birth is a common cause of morbidity and mortality in newborn infants. Cervical insufficiency (CI) is a significant cause of preterm birth. The treatment for CI is cerclage, which is a suture placed around the cervix to provide mechanical support. Cerclage, however, is associated with limited efficacy. Here we present an injectable, silk-based hydrogel as an alternative to cerclage. Objective: Pregnant rabbits were used as an animal model of pregnancy to study the mechanical properties, biocompatibility, and degradation of the hydrogel after cervical injection. Study Design: Silk hydrogel (200 μL volume) was injected into the cervix. Controls were either injected with saline or treated with cerclage (5-0 polyethylene terephthalate suture). To study the effect on mechanical properties, the cervix was tested in compression. Biodegradation of the hydrogel was followed over 6 weeks. For biocompatibility, expression levels of proinflammatory mediators were studied. Results: Hydrogel injection resulted in significant tissue augmentation—the cross-sectional area of the cervix increased 46.3 ± 3.0%. The modulus of the uninjected and hydrogel-injected tissues was 3.3 ± 0.7 and 3.2 ± 0.5 kPa at 5–10% strain, respectively ( p = 0.8). Histology showed a mild inflammatory response surrounding the hydrogel. Biodegradation of the hydrogel showed 70% volume loss over 6 weeks. Hydrogel-injected tissue showed similar inflammatory response compared with cerclage. Conclusions: In pregnant rabbits, cervical injection of the silk-based hydrogel was biocompatible and naturally degraded. No adverse effects on timing of delivery and pup viability were seen. Silk-based hydrogels show promise for tissue augmentation during pregnancy. Impact Statement: This research describes the use of injectable silk-based hydrogel for augmenting cervical tissue in vivo in a pregnant rabbit model. Further preclinical development of the methods and insights described in this article can lead to therapeutic use of this hydrogel as an alternative to cerclage in preterm birth due to cervical insufficiency.
- 6 January 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (5) , 1215-1221
Cervical Augmentation with an Injectable Silk-Based Gel: Biocompatibility in a Rat Model of Pregnancy
The aim of this study was to study the biocompatibility of an injectable silk gel in the cervix in a rat model of pregnancy. The rationale is to study an injectable gel as an alternate treatment for cervical insufficiency. We further aimed to perform cervical injections via a vaginal route to mimic the clinical procedure of a cervical cerclage. We performed an in vivo study in pregnant female Sprague Dawley rats. Cervical procedures were performed using a customized speculum under general anesthesia. Injections were performed on gestational day 16. The responses to silk gel injections were compared to polyethylene terephthalate suture and saline controls on gestational day 19 and postpartum. The inflammatory response was evaluated by histology, PCR for inflammatory gene expression, and ELISA for protein levels of proinflammatory mediators. Silk gel injections were performed on 13 animals. All animals tolerated the procedure. Silk gel occupied 5% of the stroma after injection. Injected silk gel caused neither preterm birth nor prolonged pregnancy and had no effect on the kits. When comparing inflammatory responses, expression of inflammatory genes and proinflammatory proteins in the silk gel group was intermediate between saline (lowest) and cerclage suture (highest). Injectable silk gel was more inflammatory compared to saline injections but less inflammatory compared to the suture material used for cervical cerclage. This study is an important step toward development of an alternative treatment for cervical insufficiency.
- 6 January 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (5) , 1215-1221
Cervical Augmentation with an Injectable Silk-Based Gel: Biocompatibility in a Rat Model of Pregnancy
The aim of this study was to study the biocompatibility of an injectable silk gel in the cervix in a rat model of pregnancy. The rationale is to study an injectable gel as an alternate treatment for cervical insufficiency. We further aimed to perform cervical injections via a vaginal route to mimic the clinical procedure of a cervical cerclage. We performed an in vivo study in pregnant female Sprague Dawley rats. Cervical procedures were performed using a customized speculum under general anesthesia. Injections were performed on gestational day 16. The responses to silk gel injections were compared to polyethylene terephthalate suture and saline controls on gestational day 19 and postpartum. The inflammatory response was evaluated by histology, PCR for inflammatory gene expression, and ELISA for protein levels of proinflammatory mediators. Silk gel injections were performed on 13 animals. All animals tolerated the procedure. Silk gel occupied 5% of the stroma after injection. Injected silk gel caused neither preterm birth nor prolonged pregnancy and had no effect on the kits. When comparing inflammatory responses, expression of inflammatory genes and proinflammatory proteins in the silk gel group was intermediate between saline (lowest) and cerclage suture (highest). Injectable silk gel was more inflammatory compared to saline injections but less inflammatory compared to the suture material used for cervical cerclage. This study is an important step toward development of an alternative treatment for cervical insufficiency.